How many drugs treat Gonorrhea?

Drug Landscape tracks 10 marketed treatments for Gonorrhea (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/gonorrhea.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Gonorrhea — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gonorrhea (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Gonorrhea, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Tomefloxacin	GREPAFLOXACIN	Otsuka	grepafloxacin	Potassium voltage-gated channel subfamily H member 2	1997-01-01
Ceftin	CEFUROXIME AXETIL	GSK	Cephalosporin Antibacterial		1987-01-01
Rocephin	ceftriaxone	Generic (originally Roche)	Cephalosporin antibiotic (third-generation)	Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A	1984-12-21
Zinacef	CEFUROXIME	GSK	Cephalosporin Antibacterial	Carbonic anhydrase 2	1983-01-01
Minocycline Hydrochloride	MINOCYCLINE	Rempex	Tetracycline-class Drug		1971-01-01
Vibramycin	doxycycline	Generic (originally Pfizer)	Tetracycline antibiotic	72 kDa type IV collagenase, Stromelysin-1, Collagenase 3	1967-01-01
Unasyn	AMPICILLIN	Bristol-Myers Squibb	Penicillin-class Antibacterial	Transient receptor potential cation channel subfamily M member 4	1965-01-01
Abelcet	AMPHOTERICIN B	Astellas Pharma	Lipid-based Polyene Antifungal [EPC]		1964-01-01
Benzamycin	Erythromycin Lactobionate	Pfizer	Macrolide	Potassium voltage-gated channel subfamily H member 2	1964-01-01
Demethylchlortetracycline	DEMECLOCYCLINE	Pfizer	Tetracycline-class Antimicrobial	Estrogen receptor beta	1960-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 11 drugs in Gonorrhea
GSK · 2 drugs in Gonorrhea
Pfizer · 2 drugs in Gonorrhea
Bristol-Myers Squibb · 1 drug in Gonorrhea
Bulovka Hospital · 1 drug in Gonorrhea
Centre Hospitalier Universitaire Vaudois · 1 drug in Gonorrhea
Generic (originally Abbott/Lilly) · 1 drug in Gonorrhea
Generic (originally Pfizer) · 1 drug in Gonorrhea
Generic (originally Roche) · 1 drug in Gonorrhea
Johnson And Johnson · 1 drug in Gonorrhea
Les Laboratoires des Médicaments Stériles · 1 drug in Gonorrhea
Otsuka · 1 drug in Gonorrhea

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Gonorrhea:

Cite this brief

Drug Landscape (2026). Gonorrhea — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/gonorrhea. Accessed 2026-06-10.

Gonorrhea full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing